Search
ESMO 2016: all anti PD1/PDL1 checkpoint inhibitors are not the same
Pressure on anti PD-L1s: ESMO 2016 increases the body of evidence that anti PD-L1s from Roche, Astra and PFE/MRCG may fall short of PD-1s from Bristol and Merck in various cancers and lines of treatment
